| Higher | Article quality* | Lower |
|
PlotThe frontier is the red band.
The frontier is defined as containing those trials for which there are no trials both more recent and published in a journal with a AI Score higher than the specified width of the frontier.
|
Citations found
Total: 6
Frontier
Hypothesis: These studies are considered in the Frontier and should be reviewed by a clinician needing to make a decision.
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005. PMID: 16310551 AI Score: 14.57
- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999. PMID: 10438259 AI Score: 21.64
- Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987. PMID: 3313041 AI Score: 21.64
Citations not on frontier
Hypothesis: These citations are considered outside of the frontier and could safely be ignored by a clinician needing to make a decision.
- Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002. PMID: 12433762 AI Score: 6.287
- Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000. PMID: 10880410 AI Score: 6.02
- Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993. PMID: 8435186 AI Score: 1.628
Additional citations below the limits of the plot.
No citations
Article influence score not available
No citations
|